Cystic Fibrosis and CF-Related Disorders via the CFTR Gene
Use
This test is intended for individuals with relevant features who have a clinical or suspected diagnosis of cystic fibrosis (CF) or CFTR-related disorders (CFTR-RD). It is also suitable for those who have a clinical or suspected diagnosis of CF with a single variant identified on targeted CFTR panel testing and for reproductive partners of individuals with a known pathogenic variant in the CFTR gene.
Special Instructions
STAT testing is available for expedited results delivery. Prenatal and targeted family testing options are provided. Ensure that associated forms and requisition documents are completed for accurate processing of samples.
Limitations
The test is not suitable for US FDA clearance or approval, and while validated under CLIA and CAP standards, it does not cover every potential genetic variant related to the disorders it addresses. Interpretation is dependent on the clinical context and provided clinical information.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided